

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJHM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 3 MAR 16 CASREACT coverage extended
NEWS 4 MAR 20 MARPAT now updated daily
NEWS 5 MAR 22 LWPI reloaded
NEWS 6 MAR 30 RDISCLOSURE reloaded with enhancements
NEWS 7 APR 02 JICST-EPLUS removed from database clusters and STN
NEWS 8 APR 30 GENBANK reloaded and enhanced with Genome Project ID field
NEWS 9 APR 30 CHEMCATS enhanced with 1.2 million new records
NEWS 10 APR 30 CA/CAPLUS enhanced with 1870-1889 U.S. patent records
NEWS 11 APR 30 INPADOC replaced by INPADOCDB on STN
NEWS 12 MAY 01 New CAS web site launched
NEWS 13 MAY 08 CA/CAPLUS Indian patent publication number format defined
NEWS 14 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 15 MAY 21 BIOSIS reloaded and enhanced with archival data
NEWS 16 MAY 21 TOXCENTER enhanced with BIOSIS reload
NEWS 17 MAY 21 CA/CAPLUS enhanced with additional kind codes for German patents
NEWS 18 MAY 22 CA/CAPLUS enhanced with IPC reclassification in Japanese patents
NEWS 19 JUN 27 CA/CAPLUS enhanced with pre-1967 CAS Registry Numbers
NEWS 20 JUN 29 STN Viewer now available
NEWS 21 JUN 29 STN Express, Version 8.2, now available
NEWS 22 JUL 02 LEMBASE coverage updated
NEWS 23 JUL 02 LMEDLINE coverage updated
NEWS 24 JUL 02 SCISEARCH enhanced with complete author names
NEWS 25 JUL 02 CHEMCATS accession numbers revised
NEWS 26 JUL 02 CA/CAPLUS enhanced with utility model patents from China

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 4 MAY 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:13:18 ON 02 JUL 2007

=> FILE REGISTRY
COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:13:28 ON 02 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

```
STRUCTURE FILE UPDATES:      1 JUL 2007  HIGHEST RN 940612-32-8
DICTIONARY FILE UPDATES:    1 JUL 2007  HIGHEST RN 940612-32-8
```

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

```
=>
Uploading C:\Program Files\Stnexp\Queries\10564844a.str
```



```

chain nodes :
10 11 24 25 26 27 28 29 30
ring nodes :
1 2 3 4 5 6 7 8 9 12 13 14 15 16 17 18 19 20 21 22 23
chain bonds :
1-10 3-11 7-18 11-12 14-25 22-24 25-30 25-26 26-27 27-28 28-29
ring bonds :

```

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 12-13 12-17 13-14 14-15 15-16
 16-17 18-19 18-23 19-20 20-21 21-22 22-23
 exact/norm bonds :
 3-11 5-7 6-9 7-8 7-18 8-9 11-12 25-30 25-26
 exact bonds :
 1-10 14-25 22-24 26-27 27-28 28-29
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17 18-19
 18-23 19-20 20-21 21-22 22-23

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
 11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
 20:Atom 21:Atom 22:Atom 23:Atom 24:CLASS 25:CLASS 26:CLASS 27:CLASS
 28:CLASS 29:CLASS 30:CLASS

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 16:13:51 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED 1 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**

PROJECTED ITERATIONS: 1 TO 80
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 16:13:54 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 7 TO ITERATE

100.0% PROCESSED 7 ITERATIONS


1 ANSWERS

SEARCH TIME: 00.00.01

L3 1 SEA SSS FUL L1

=> d scan

L3 1 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzanide, 3-[[3-(3-fluorophenyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-
yl]amino]-N-(2-hydroxyethyl)- (9CI)
MF C19 H16 F N7 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
172.10	172.31

FILE 'CAPLUS' ENTERED AT 16:14:08 ON 02 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Jul 2007 VOL 147 ISS 2
FILE LAST UPDATED: 1 Jul 2007 (20070701/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 1 L3

=> d l4 ibib abs hitstr

ACCESSION NUMBER: 2005:122890 CAPLUS

DOCUMENT NUMBER: 142:219305

TITLE: Preparation of triazolopyrimidines as glycogen

synthase kinase 3 inhibitors

INVENTOR(S): Freyna, Eddy Jean Edgard; Love, Christopher John;
Coomans, Ludwig Paul; Vandermaesen, Nele; Buijnsters,
Peter Jacobus Johannes Antonius; Willems, Marc;
Embrechts, Werner Constant Johan

Janssen Pharmaceutica N.V., Belg.

PCT Int. Appl., 124 pp.

SOURCE: CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012307	A1	20050210	WO 2004-EP51455	20040712
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TH, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, HR, NE, SN, TD, TG				
AU 2004260738	A1	20050210	AU 2004-260738	20040712
CA 2531333	A1	20050210	CA 2004-2531333	20040712
EP 1658292	A1	20060524	EP 2004-766189	20040712
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1823068	A	20060823	CN 2004-80020148	20040712
BR 2004012596	A	20060919	BR 2004-12596	20040712
US 2006205721	A1	20060914	US 2006-564844	20060113
NO 2006000678	A	20060210	NO 2006-678	20060210
PRIORITY APPLN. INFO.:			WO 2003-EP350310	A 20030716
			WO 2004-EP51455	W 20040712
OTHER SOURCE(S):			CASREACT 142:219305; MARPAT 142:219305	
GI				




AB The title compds. I [ring A = Ph, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl; R1 = H, aryl, formyl, etc.; X = a direct bond, (CH2)_n or (CH2)_mX1aX1b (n = 1-4; m = 1-2; X1a = O, C(O), NR5; X1b = a direct bond, alkyl); R2 = cycloalkyl, Ph, 4-7 membered monocyclic heterocycle containing

at least one heteroatom, selected from O, S or N, benzoxazolyl, etc.; R3 = halo, OH, (un)substituted alkyl, alkenyl or alkynyl, etc.; R4 = H, halo, OH, (un)substituted alkyl, etc.; R5 = H, alkyl, alkenyl, useful for the prevention or the treatment of diseases mediated through GSK3, were prepared E.g., a 4-step synthesis of II which showed pIC50 of > 8 against GSK3β and against GSK3α, was given. The pharmaceutical composition comprising the compound I is disclosed.

IT 840535-34-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazolopyrimidines as glycogen synthase kinase 3 inhibitors)

RN 840535-34-4 CAPLUS
CN Benzamide, 3-[[3-(3-fluorophenyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file registry
COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
5.74	178.05

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

SINCE FILE ENTRY	TOTAL SESSION
-0.78	-0.78

FILE 'REGISTRY' ENTERED AT 16:14:46 ON 02 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 1 JUL 2007 HIGHEST RN 940612-32-8
DICTIONARY FILE UPDATES: 1 JUL 2007 HIGHEST RN 940612-32-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10564844b.str



```

chain nodes :
10 11 19 21
ring nodes :
1 2 3 4 5 6 7 8 9 12 13 14 15 16 17
chain bonds :
1-10 3-11 7-19 11-12 11-21
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 12-13 12-17 13-14 14-15 15-16
16-17
exact/norm bonds :
3-11 5-7 6-9 7-8 7-19 8-9 11-12 11-21
exact bonds :
1-10
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17

```

G1: Cy, H, Ak, C

G2: H, C, Cb, Ak

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 19:CLASS 21:CLASS


```

L5 STRUCTURE UPLOADED

=> d 15

L5 HAS NO ANSWERS

L5 STR



G1 Cy,H,Ak,C

G2 H,C,Cb,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s 15

SAMPLE SEARCH INITIATED 16:15:14 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 132 TO ITERATE

100.0% PROCESSED 132 ITERATIONS

28 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**


PROJECTED ITERATIONS: 1951 TO 3329

PROJECTED ANSWERS: 243 TO 877

L6 28 SEA SSS SAM L5

=> d scan


L6 28 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Benzenesacetamide, 3-([5-([3-(5-oxazolyl)phenyl]amino)-3H-1,2,3-triazolo(4,5-
 d)pyrimidin-3-yl]- (9CI)
 MF C21 H16 N8 O2



''PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT''

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 28 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Benzoic acid, 2-(acetlamino)-5-([3-([3-([methoxyacetyl]amino)methyl]phenyl)-3H-1,2,3-triazolo(4,5-d)pyrimidin-5-yl]amino)-, methyl ester (9CI)
 MF C24 H24 N8 O5



''PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT''

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s 15 full sss
FULL SEARCH INITIATED 16:17:44 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2448 TO ITERATE

100.0% PROCESSED 2448 ITERATIONS
SEARCH TIME: 00.00.01


601 ANSWERS

L7 601 SEA SSS FUL L5

=> d scan


L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:884440 CAPLUS
DOCUMENT NUMBER: 145:293080
TITLE: Preparation and GSK-3 modulation of
2,4,5-trisubstituted pyrimidine and bicyclic
2-aminopyrimidine derivatives
INVENTOR(S): Sebo, Lubomir; Kahl, Jeffrey; Lum, Christopher; Pei,
Yazhong; Pryor, Kent E.; Urban, Jan; Jones, Bryan;
Sullivan, Robert
PATENT ASSIGNEE(S): Kemia, Inc., USA
SOURCE: PCT Int. Appl., 119pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006091737	A1	20060831	WO 2006-US6447	20060223
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HD, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, HR, NE, SN, TD, TO, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.: US 2005-656265P P 20050224 US 2005-691519P P 20050617 US 2005-725369P P 20051011				
OTHER SOURCE(S): MARPAT 145:293080				
GI				




AB 2,4,5-Trisubstituted pyrimidine and bicyclic 2-aminopyrimidine derivs. I, wherein A is (un)substituted alkyl, halo, cyano, nitro, amine, B and C are independently NH, CH2 or carbonyl; R1 is (un)substituted cycloalkyl or cycloalkenyl; R2 is (un)substituted Me, (un)substituted cycloalkyl, (un)substituted cycloalkenyl groups are prepared. Thus, II was prepared and displayed >40% inhibition in either GSK-3a or GSK-3b assay at


L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-1H-indazol-6-yl-3-phenyl- (9C1) (CA INDEX NAME)




RN 908299-60-5 CAPLUS
CN 1(3H)-Isobenzofuranone, 5-[[3-(4-(1,1-dimethylethyl)phenyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]- (9C1) (CA INDEX NAME)



RN 908299-63-8 CAPLUS
CN 1(3H)-Isobenzofuranone, 5-[[3-(2-methylphenyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]- (9C1) (CA INDEX NAME)



RN 908299-66-1 CAPLUS
CN 1(3H)-Isobenzofuranone, 5-[[3-(2-methoxyphenyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]- (9C1) (CA INDEX NAME)



L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
10 μ M. Due to their ability to modulate GSK-3 activity, I can be used as prodrugs in the treatment of CNS diseases, such as Alzheimer's disease and mood disorders, and metabolic diseases, such as insulin requiring states.


IT 908299-40-1P 908299-41-2P 908299-45-6P
908299-52-5P 908299-60-5P 908299-63-8P
908299-66-1P 908299-69-4P 908299-71-8P
908299-72-9P 908300-03-8P 908300-05-0P
908300-11-8P 908300-13-0P 908300-19-6P
908300-33-4P 908300-43-6P 908300-44-7P
908300-48-1P 908300-49-2P 908300-70-9P
908301-54-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and GSK-3 modulation of 2,4,5-trisubstituted pyrimidine and bicyclic 2-aminopyrimidine derivs.)


RN 908299-40-1 CAPLUS

CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-phenyl- (9C1) (CA INDEX NAME)




RN 908299-41-2 CAPLUS

CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-1,3-benzodioxol-5-yl-3-phenyl- (9C1) (CA INDEX NAME)



RN 908299-45-6 CAPLUS


CN 1H-isoindole-1,3(2H)-dione, 5-[[3-(3-phenyl-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl)amino]- (9C1) (CA INDEX NAME)



RN 908299-52-5 CAPLUS


L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 908299-69-4 CAPLUS
CN 1(3H)-Isobenzofuranone, 5-[[3-(2-chlorophenyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]- (9C1) (CA INDEX NAME)




RN 908299-71-8 CAPLUS

CN 1(3H)-Isobenzofuranone, 5-[[3-(4-(trifluoromethyl)phenyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]- (9C1) (CA INDEX NAME)




RN 908299-72-9 CAPLUS

CN 1(3H)-Isobenzofuranone, 5-[[3-(3-phenyl-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl)amino]- (9C1) (CA INDEX NAME)




RN 908300-03-8 CAPLUS


CN 1H-isoindol-1-one, 2,3-dihydro-5-[[3-(4-methylphenyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]- (9C1) (CA INDEX NAME)





RN 908300-05-0 CAPLUS
CN 1H-isoindol-1-one, 5-[[3-[[4-(1,1-dimethylethyl)phenyl]-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 908300-11-8 CAPLUS
CN 1H-isoindol-1-one, 2,3-dihydro-5-[[3-(1-methylethyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]- (9CI) (CA INDEX NAME)




RN 908300-13-0 CAPLUS
CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, 3-[[4-(1,1-dimethylethyl)phenyl]-N-[2-(trifluoromethyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 908300-49-2 CAPLUS
CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, 3-(2,3-dihydro-1H-inden-5-yl)-N-1H-indazol-6-yl- (9CI) (CA INDEX NAME)




RN 908300-70-9 CAPLUS
CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-1H-benzotriazol-5-yl-3-phenyl- (9CI) (CA INDEX NAME)




RN 908301-54-2 CAPLUS
CN 1(3H)-isobenzofuranone, 6-[[3-phenyl-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]- (9CI) (CA INDEX NAME)




RN 908300-19-6 CAPLUS
CN 1(3H)-isobenzofuranone, 5-[[3-(cyclopentyl-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]- (9CI) (CA INDEX NAME)




RN 908300-33-4 CAPLUS
CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-1H-indazol-6-yl-3-tricyclo[3.3.1.1^{3,7}]dec-1-yl- (9CI) (CA INDEX NAME)




RN 908300-43-6 CAPLUS
CN 1(3H)-isobenzofuranone, 5-[[3-(2,3-dihydro-1H-inden-5-yl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]- (9CI) (CA INDEX NAME)




RN 908300-44-7 CAPLUS
CN 1H-inden-1-one, 2,3-dihydro-5-[[3-phenyl-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]- (9CI) (CA INDEX NAME)




RN 908300-48-1 CAPLUS
CN 1H-isoindole-1,3(2H)-dione, 5-[[3-(2,3-dihydro-1H-inden-5-yl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]- (9CI) (CA INDEX NAME)



RN 840536-76-7 CAPLUS
CN Benzoic acid, 2-(acetylamino)-5-[[3-[(3-cyanomethyl)phenyl]-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 840536-77-8 CAPLUS
CN Benzonitrile, 3-[[3-[(2-hydroxyethyl)phenyl]-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]- (9CI) (CA INDEX NAME)




RN 840536-78-9 CAPLUS
CN Benzeneethanol, 3-[5-[[4-[(2-hydroxyethyl)phenyl]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 840536-82-5 CAPLUS
CN Benzeneacetoneitrile, 3-[5-[[4-[(2-hydroxyethyl)phenyl]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)



RN 840536-83-6 CAPLUS
CN Carbamic acid, [[3-[[5-[[4-[(2-hydroxyethyl)phenyl]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 840536-84-7 CAPLUS
CN Benzamide, 3-[[3-[(3-cyanomethyl)phenyl]-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 840536-85-8 CAPLUS
CN Benzeneethanol, 3-[5-[[3-[(2-hydroxyethyl)phenyl]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)


L9 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 840536-79-0 CAPLUS
CN Benzeneethanol, 3-[5-[[3-[(2-methoxyethoxy)phenyl]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 840536-80-3 CAPLUS
CN Methanesulfonamide, N-[3-[[3-[(3-cyanomethyl)phenyl]-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 840536-81-4 CAPLUS
CN Benzeneacetoneitrile, 3-[5-[[3-[(methoxymethyl)phenyl]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




L9 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 840536-86-9 CAPLUS
CN Benzamide, 3-[[3-[(3-cyanomethyl)phenyl]-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 840536-87-0 CAPLUS
CN Benzamide, 3-[[3-[(3-cyanomethyl)phenyl]-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 840536-88-1 CAPLUS
CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, 3-[3-[(aminomethyl)phenyl]-N-(4-fluorophenyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


IT 840536-89-2P 840536-90-5P 840536-91-6P
 840536-92-7P 840536-94-9P 840536-95-0P
 840536-96-1P 840536-97-2P 840536-98-3P
 840536-99-4P 840537-00-0P 840537-01-1P
 840537-02-2P 840537-03-3P 840537-04-4P
 840537-05-5P 840537-06-6P 840537-08-8P
 840537-09-9P 840537-10-2P 840537-11-3P
 840537-12-4P 840537-13-5P 840537-14-6P
 840537-15-7P 840537-16-8P 840537-17-9P
 840537-18-0P 840537-19-1P 840537-20-4P
 840537-21-5P 840537-22-6P 840537-23-7P
 840537-24-8P 840537-25-9P 840537-26-0P
 840537-27-1P 840537-28-2P 840537-29-3P
 840537-30-6P 840537-31-7P 840537-32-8P
 840537-33-9P 840537-34-0P 840537-35-1P
 840537-36-2P 840537-37-3P 840537-38-4P
 840537-39-5P 840537-40-8P 840537-79-3P
 840537-80-6P 840537-85-1P 840537-88-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of triazolopyrimidines as glycogen synthase kinase 3 inhibitors)
 RN 840536-89-2 CAPLUS
 CN Benzonitrile, 4-([3-[(2-hydroxyethyl)phenyl]-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino)- (9CI) (CA INDEX NAME)




RN 840536-90-5 CAPLUS
 CN Benzeneacetonitrile, 3-[5-[(3-cyanophenyl)amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 840536-95-0 CAPLUS
 CN Acetamide, N-([3-[(4-fluorophenyl)amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 840536-96-1 CAPLUS
 CN Benzamide, 4-([3-[(2-methoxyethoxy)methyl]phenyl]-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino)- (9CI) (CA INDEX NAME)




RN 840536-97-2 CAPLUS
 CN Benzeneethanol, 4-[5-[(4-fluorophenyl)amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 840536-91-6 CAPLUS
 CN Benzamide, 4-([3-[(3-cyanomethyl)phenyl]-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino)- (9CI) (CA INDEX NAME)




RN 840536-92-7 CAPLUS
 CN Benzeneacetonitrile, 3-[5-[(3-(2-hydroxyethyl)phenyl)amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 840536-94-9 CAPLUS
 CN Benzeneacetonitrile, 3-[5-[(3-(1-hydroxyethyl)phenyl)amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 840536-98-3 CAPLUS
 CN Benzeneethanol, 4-([3-[(2-methoxyethoxy)methyl]phenyl]-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino)- (9CI) (CA INDEX NAME)




RN 840536-99-4 CAPLUS
 CN Benzeneethanol, 4-[5-[(4-(2-hydroxyethyl)phenyl)amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 840537-00-0 CAPLUS
 CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-[4-(aminomethyl)phenyl]-3-(3-fluorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




RN 840537-37-3 CAPLUS
CN Benzamide, 4-[[3-[[3-(cyanomethyl)phenyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 840537-38-4 CAPLUS
CN Benzamide, 4-[[3-[[3-(methoxymethyl)phenyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 840537-39-5 CAPLUS
CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-(4-chlorophenyl)-3-[[3-[(2-methoxyethoxy)methyl]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 840537-40-8 CAPLUS
CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-(4-chlorophenyl)-3-[[3-(methoxymethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 840537-79-3 CAPLUS
CN Benzeneethanol, 3-[5-[[4-[(2-aminoethyl)phenyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 840537-80-6 CAPLUS
CN Benzeneethanol, 3-[5-[[4-[[[(2,2,2-trifluoroethyl)amino]methyl]phenyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)



RN 840537-85-1 CAPLUS
CN Benzeneacetonitrile, 3-[5-[[4-[(aminomethyl)phenyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 840537-88-4 CAPLUS
CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, 3-(3-fluorophenyl)-N-[[4-[[2,2,2-trifluoroethyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2005:122889 CAPLUS
DOCUMENT NUMBER: 142:219304
TITLE: Preparation of triazolopyrimidines as glycogen synthase kinase 3 inhibitors
INVENTOR(S): Freyne, Eddy Jean; Edgarty, Love, Christopher John; Coomans, Ludwig Paul; Vandermaesen, Neler; Buijnsters, Peter Jacobus Johannes Antonius; Willems, Marc; Embrechts, Werner Constant Johan
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012304	A2	20050210	WO 2004-EP51457	20040712
WO 2005012304	A3	20070426		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AF, EA, EP, OA				
AU 2004260739	A1	20050210	AU 2004-260739	20040712
CA 2531232	A1	20050210	CA 2004-2531232	20040712
CN 1938308	A	20070328	CN 2004-80020418	20040712
EP 1781659	A2	20070509	EP 2004-766191	20040712
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, HR, LT, LV, MK				
US 2006183747	A1	20060817	US 2006-565065	20060117
PRIORITY APPLN. INFO.: WO 2003-EP50314 A 20030716				
WO 2003-EP350314 A 20030716				
WO 2004-EP51457 W 20040712				
OTHER SOURCE(S): CASREACT 142:219304; MARPAT 142:219304				
GI				



I



II

AB The title compds. I [ring A = Ph, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl; R1 = H, aryl, formyl, etc.; X = a direct bond, (CH2)n or (CH2)mX1aX1b (n = 1-4; m = 1-2; X1a = O, C(O), NR5; X1b = a direct bond, alkyl); R2 = cycloalkyl, Ph, 4-7 membered monocyclic heterocycle containing


at least one heteroatom, selected from O, S or N, benzoxazolyl, etc.; X2 = a direct bond, O, C(O), etc.; R3 = (un)substituted 5-6 membered monocyclic heterocyclyl or 9-10 membered bicyclic heterocyclyl, etc.; R4 = H, halo, OH, (un)substituted alkyl, etc.; R5 = H, alkyl, alkenyl], useful for the prevention or the treatment of diseases mediated through GSK3, were prepared E.g., a 4-step synthesis of II which showed pIC50 of > 8 against GSK3β and against GSK3α, was given. The pharmaceutical composition comprising the compound I is disclosed.

IT 842127-58-6P 842128-38-5P

RI: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of triazolopyrimidines as glycogen synthase kinase 3 inhibitors)

RN 842127-58-6 CAPLUS

CN Acetamide, 2-methoxy-N-[[3-[5-[[3-(5-oxazolyl)phenyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)




842128-85-2P 842128-86-3P 842128-87-4P
842128-88-5P 842128-89-6P 842128-90-9P
842128-91-0P 842128-92-1P 842128-93-2P
842128-94-3P 842128-95-4P 842128-96-5P
842128-97-6P 842128-98-7P 842128-99-8P
842129-00-4P 842129-01-5P 842129-27-5P
842129-28-6P

RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of triazolopyrimidines as glycogen synthase kinase 3 inhibitors)


RN 842127-49-5 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 5-[3-[[3-(3-fluorophenyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]phenyl]-1,2-dihydro- (9CI) (CA INDEX NAME)




RN 842127-50-8 CAPLUS

CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, 3-(3-bromophenyl)-N-[3-(2,5-dihydro-1H-imidazol-4-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 842127-51-9 CAPLUS

CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, 3-(3-bromophenyl)-N-[4-(1H-1,2,4-triazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 842128-38-5 CAPLUS

CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, 3-(3-bromophenyl)-N-[3-(1-methyl-1H-pyrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)




IT 842127-49-5P 842127-50-8P 842127-51-9P

842127-52-0P 842127-53-1P 842127-54-2P
842127-55-3P 842127-56-4P 842127-57-5P
842127-59-7P 842127-60-0P 842127-61-1P
842127-62-2P 842127-63-3P 842127-64-4P
842127-65-5P 842127-66-6P 842127-67-7P
842127-68-8P 842127-69-9P 842127-70-2P
842127-71-3P 842127-72-4P 842127-73-5P
842127-74-6P 842127-75-7P 842127-76-8P
842127-77-9P 842127-78-0P 842127-79-1P
842127-80-4P 842127-81-5P 842127-82-6P
842127-83-7P 842127-84-8P 842127-85-9P
842127-86-0P 842127-87-1P 842127-88-2P
842127-89-3P 842127-90-6P 842127-91-7P
842127-92-8P 842127-93-9P 842127-94-0P
842127-95-1P 842127-96-2P 842127-97-3P
842127-98-4P 842127-99-5P 842128-00-1P
842128-01-2P 842128-02-3P 842128-03-4P
842128-04-5P 842128-05-6P 842128-06-7P
842128-07-8P 842128-08-9P 842128-09-0P
842128-10-3P 842128-11-4P 842128-13-6P
842128-14-7P 842128-15-8P 842128-16-9P
842128-17-0P 842128-18-1P 842128-19-2P
842128-20-5P 842128-21-6P 842128-22-7P
842128-23-8P 842128-24-9P 842128-25-0P
842128-26-1P 842128-27-2P 842128-28-3P
842128-29-4P 842128-30-7P 842128-31-8P
842128-32-9P 842128-33-0P 842128-34-1P
842128-35-2P 842128-36-3P 842128-37-4P
842128-39-6P 842128-40-9P 842128-41-0P
842128-42-1P 842128-43-2P 842128-44-3P
842128-45-4P 842128-46-5P 842128-47-6P
842128-48-7P 842128-49-8P 842128-50-1P
842128-52-3P 842128-53-4P 842128-54-5P
842128-55-6P 842128-56-7P 842128-57-8P
842128-58-9P 842128-59-0P 842128-62-5P
842128-63-6P 842128-64-7P 842128-65-8P
842128-66-9P 842128-67-0P 842128-68-1P
842128-69-2P 842128-70-5P 842128-71-6P
842128-72-7P 842128-73-8P 842128-74-9P
842128-75-0P 842128-76-1P 842128-77-2P
842128-78-3P 842128-79-4P 842128-80-7P
842128-81-8P 842128-83-0P 842128-84-1P


RN 842127-52-0 CAPLUS

CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, 3-(3-fluorophenyl)-N-[3-(3-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 842127-53-1 CAPLUS

CN Benzenethanol, 3-[5-[[4-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 842127-54-2 CAPLUS

CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, 3-(3-fluorophenyl)-N-(3-pyrazinylphenyl)- (9CI) (CA INDEX NAME)




RN 842127-55-3 CAPLUS


CN Benzeneacetone trile, 3-[5-[[3-(2-amino-4-pyrimidinyl)phenyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 842127-56-4 CAPLUS
CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, 3-(3-fluorophenyl)-N-[3-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 842127-57-5 CAPLUS
CN Acetamide, N-[[3-[[3-(5-oxazolyl)phenyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 842127-59-7 CAPLUS
CN Benzeneacetonitrile, 3-[5-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 842127-60-0 CAPLUS
CN Carbamic acid, [[3-[[3-(5-oxazolyl)phenyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 842127-61-1 CAPLUS
CN Tricyclo[3.3.1.1,3,7]decane-1-carboxamide, N-[[3-[[3-(2-amino-4-pyrimidinyl)phenyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 842127-62-2 CAPLUS
CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, 3-cyclohexyl-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 842127-63-3 CAPLUS
CN Benzenemethanol, 3-[5-[[3-(5-oxazolyl)phenyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 842127-64-4 CAPLUS
CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, 3-cyclohexyl-N-[4-(4-morpholinyl)-3-nitrophenyl]- (9CI) (CA INDEX NAME)




RN 842127-65-5 CAPLUS
CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, 3-cyclohexyl-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 842127-66-6 CAPLUS
CN Benzamide, 3-[5-[[3-(1-methyl-1H-imidazol-2-yl)phenyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 842127-67-7 CAPLUS
CN Cyanamide, [4-(3-[[3-(3-fluorophenyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]phenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 842127-68-8 CAPLUS
CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, 3-(3-fluorophenyl)-N-[3-(2-methylamino)-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 842127-69-9 CAPLUS
CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-[3-(2-amino-4-pyrimidinyl)phenyl]-N-ethyl-3-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 842127-70-2 CAPLUS
CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-ethyl-3-(3-fluorophenyl)-N-(3-(2-methyl-4-pyrimidinyl)phenyl)- (9CI) (CA INDEX NAME)




RN 842127-71-3 CAPLUS
CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, 3-(3-fluorophenyl)-N-(3-(1H-pyrazol-3-yl)phenyl)- (9CI) (CA INDEX NAME)




RN 842127-72-4 CAPLUS
CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-(3-(1-methyl-1H-pyrazol-5-yl)phenyl)-3-phenyl- (9CI) (CA INDEX NAME)




RN 842127-73-5 CAPLUS
CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, 3-(3-(aminomethyl)phenyl)-N-(3-phenyl)- (9CI) (CA INDEX NAME)




RN 842127-76-0 CAPLUS
CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-(4-(4-morpholinyl)phenyl)-3-phenyl- (9CI) (CA INDEX NAME)




RN 842127-79-1 CAPLUS
CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-(4-(4-methyl-1-piperazinyl)phenyl)-3-phenyl- (9CI) (CA INDEX NAME)




RN 842127-80-4 CAPLUS
CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-(3-(1-methyl-1H-imidazol-2-yl)phenyl)-3-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 842127-81-5 CAPLUS
CN Benzeneethanol, 3-[5-[[3-(4-bromo-1-methyl-1H-pyrazol-3-yl)phenyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 842127-74-6 CAPLUS
CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-[3-(5-oxazolyl)phenyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 842127-75-7 CAPLUS
CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-[3-(1-methyl-1H-tetrazol-5-yl)phenyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 842127-76-8 CAPLUS
CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-[3-(2-amino-4-pyrimidinyl)phenyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 842127-77-9 CAPLUS
CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-[4-(2-methyl-2H-tetrazol-5-yl)phenyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 842127-82-6 CAPLUS
CN Benzeneethanol, 3-[5-[[3-(1H-tetrazol-5-yl)phenyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)



RN 842127-83-7 CAPLUS
CN Benzeneethanol, 3-[5-[[3-(1-methyl-1H-tetrazol-5-yl)phenyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)



RN 842127-84-8 CAPLUS
CN Benzeneethanol, 3-[5-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)